#1 Most-Profitable Drug in America Linked to Gambling Addiction, Sex Addiction
Abilify patients, including Abilify users who have incurred heavy gambling debts, have filed lawsuits against Abilify manufacturer Bristol-Myers Squibb. These suits allege links between Abilify use and damaging impulsive behavior, like uncontrollable gambling, binge eating, and hypersexual behavior, in users with no history of such conduct. The gambling addition can be so severe that patients go into extreme debt and even lose their homes.
Contact National Drug Injury Attorneys
If you or a family member have suffered losses from compulsive gambling you think may be linked to Abilify use, we welcome the chance to talk with you. In addition to potentially helping you with your Abilify related losses, learning of your experience can help others suffering from Abilify’s depravations. Please use the form below to start the conversation, or call us toll-free at 1 800 541-7358 for help with your Abilify gambling compulsions.
Bristol-Myers Squibb’s top-selling Abilify drug earned the company $6.4 billion in 2013. Prescribed for treatment of depression, bipolar disorder, and schizophrenia, Medscape notes that more than 8.8 million Abilify prescriptions were written in 2014 alone.
Abilify Injury Cases Consolidated for National Multidistrict Litigation in Florida
In October 2016, numerous Abilify patient injury lawsuits were consolidated for multidistrict litigation before Chief Judge M. Casey Rodgers of the U.S. District Court for the Northern District of Florida. In December 2016, Chief Judge Rodgers appointed Lieff Cabraser attorney Lexi J. Hazam to the Plaintiffs Executive Committee in the litigation. Ms. Hazam was also appointed to the Science and Expert Sub-Committee responsible for overseeing the Science Day presentations to the Court and organizing and coordinating expert discovery.
August 2016 Serious Abilify Warning Updates
Lieff Cabraser Files Personal Injury Lawsuit Against Bristol-Myers Squibb and Otsuka Pharmaceutical for Damages Caused by Abilify Prescription Drug
Gambling addiction lawsuit alleges claims including Strict Liability, Negligent Misrepresentation, and Fraudulent Concealment, and seeks damages for neuropsychiatric, mental, physical, and economic damages, as well as punitive damages
On July 25, 2016, Lieff Cabraser filed a personal injury lawsuit on behalf of Massachusetts resident Rikki Carlson against Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co., Ltd., and Otsuka America Pharmaceutical, Inc. (“Defendants”) for damages suffered as a direct and proximate result of Defendants’ wrongful conduct in connection with the development, design, testing, labeling, packaging, promoting, advertising, marketing, distribution, and selling of the blockbuster prescription drug Abilify. The Complaint alleges that Abilify harmed Ms. Carlson by causing compulsive behaviors including compulsive gambling, shopping, and binge eating, causing her substantial financial, mental, and physical damages.
Though it lists numerous other Abilify side effects, Bristol-Myers doesn’t even mention compulsive behavior risks on Abilify’s drug label. Abilify users who suffered extreme and debilitating debt from their Abilify-linked gambling addictions can file lawsuits against Abilify’s manufacturer to recover their losses and to get help with their ruinous debts and related psychological distresses.
Earlier Warnings on Abilify Dangers and Abilify Gambling Risks
In May 2016, the FDA issued a formal warning that the use of the antipsychotic drug aripiprazole (Abilify, Abilify Maintena, Aristada, and also used in generic versions of the drug) has been linked to compulsive urges which can lead to uncontrollable gambling, among other addictions. These rare but serious impulse-control problems reportedly stop when the medicine is discontinued or markedly reduced in dosage.
Abilify is a trademark of Otsuka Pharmaceutical Company and is used for informational and product identification purposes only. Lieff Cabraser is not affiliated in any manner with Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co., Ltd., and Otsuka America Pharmaceutical, Inc.